Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$4.81 -2.0%	$5.55	$4.71 ▼ $12.43	$695.62M	1.36	2.22 million shs	2.10 million shs
DAWN Day One Biopharmaceuticals	$15.75 +6.1%	$15.24	$9.67 ▼ $17.85	$1.38B	-1.48	635,490 shs	1.88 million shs
DICE DICE Therapeutics	$47.55	$47.31	$15.08 ▼ $47.90	$2.27B	1.03	1.03 million shs	N/A
DVAX Dynavax Technologies	$11.34 -0.8%	$12.38	$10.06 ▼ $15.15	$1.48B	1.26	1.95 million shs	2.18 million shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-1.80%	-1.60%	-3.54%	-37.69%	-55.36%
DAWN Day One Biopharmaceuticals	+1.64%	+3.05%	+6.60%	+7.69%	+17.76%
DICE DICE Therapeutics	0.00%	0.00%	0.00%	0.00%	+55.57%
DVAX Dynavax Technologies	-0.52%	-4.35%	-2.31%	-18.18%	+3.53%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	0.8183 of 5 stars	3.4	1.0	0.0	0.0	1.8	0.0	0.6
DAWN Day One Biopharmaceuticals	2.0594 of 5 stars	3.3	2.0	0.0	0.0	2.7	2.5	0.6
DICE DICE Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	4.3672 of 5 stars	3.4	1.0	0.0	4.7	3.2	2.5	1.9

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	2.75	Moderate Buy	$10.00	107.90% Upside
DAWN Day One Biopharmaceuticals	2.57	Moderate Buy	$40.60	157.78% Upside
DICE DICE Therapeutics	2.22	Hold	$55.67	17.07% Upside
DVAX Dynavax Technologies	2.75	Moderate Buy	$25.00	120.46% Upside

Current Analyst Ratings

Latest AUPH, DICE, DVAX, and DAWN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/26/2024	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$40.00
3/1/2024	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
2/28/2024	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $40.00
2/27/2024	DAWN Day One Biopharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $44.00
2/27/2024	DAWN Day One Biopharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
2/23/2024	AUPH Aurinia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $10.00
2/23/2024	DVAX Dynavax Technologies	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/22/2024	AUPH Aurinia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $13.00
2/16/2024	AUPH Aurinia Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$9.50 ➝ $9.00
2/16/2024	AUPH Aurinia Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$13.00 ➝ $8.00
2/1/2024	DVAX Dynavax Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$20.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$175.51M	3.96	N/A	N/A	$2.63 per share	1.83
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	$3.98 per share	N/A
DICE DICE Therapeutics	$1.13M	2,008.50	N/A	N/A	$10.86 per share	4.38
DVAX Dynavax Technologies	$232.28M	6.39	N/A	N/A	$4.81 per share	2.36

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	-$78.02M	-$0.54	N/A	8.75	N/A	-44.45%	-20.10%	-14.84%	5/2/2024 (Confirmed)
DAWN Day One Biopharmaceuticals	-$188.92M	-$2.38	N/A	N/A	N/A	N/A	-51.67%	-48.30%	5/6/2024 (Estimated)
DICE DICE Therapeutics	-$83.89M	-$2.34	N/A	N/A	N/A	N/A	-22.01%	-20.79%	N/A
DVAX Dynavax Technologies	-$6.39M	-$0.06	N/A	26.37	N/A	-2.75%	-1.08%	-0.66%	5/7/2024 (Estimated)

Latest AUPH, DICE, DVAX, and DAWN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/2/2024	N/A	AUPH Aurinia Pharmaceuticals	-$0.17	N/A	+$0.17	N/A	N/A	N/A
2/26/2024	Q4 2023	DAWN Day One Biopharmaceuticals	-$0.57	-$0.64	-$0.07	-$0.64	N/A	N/A
2/15/2024	12/31/2023	AUPH Aurinia Pharmaceuticals	-$0.16	-$0.19	-$0.03	-$0.19	$45.00 million	$45.10 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
DICE DICE Therapeutics	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.20	5.50	4.99
DAWN Day One Biopharmaceuticals	N/A	12.72	12.72
DICE DICE Therapeutics	N/A	25.88	32.44
DVAX Dynavax Technologies	0.41	13.81	12.96

Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
DAWN Day One Biopharmaceuticals	87.95%
DICE DICE Therapeutics	N/A
DVAX Dynavax Technologies	96.96%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	4.30%
DAWN Day One Biopharmaceuticals	8.40%
DICE DICE Therapeutics	4.90%
DVAX Dynavax Technologies	2.62%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	144.62 million	138.40 million	Optionable
DAWN Day One Biopharmaceuticals	155	87.38 million	80.04 million	Optionable
DICE DICE Therapeutics	71	47.73 million	45.39 million	Not Optionable
DVAX Dynavax Technologies	408	130.86 million	127.43 million	Optionable

AUPH, DICE, DVAX, and DAWN Headlines

Source	Headline
	Federated Hermes Inc. Sells 1,264,059 Shares of Dynavax Technologies Co. (NASDAQ:DVAX) marketbeat.com - April 18 at 12:22 PM
	Dynavax Technologies (NASDAQ:DVAX) Downgraded to "Hold" at StockNews.com americanbankingnews.com - April 18 at 5:56 AM
	StockNews.com Lowers Dynavax Technologies (NASDAQ:DVAX) to Hold marketbeat.com - April 17 at 11:13 PM
	Peregrine Capital Management LLC Decreases Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX) marketbeat.com - April 11 at 7:42 AM
	3 Biotech Buys Under $15 stocknews.com - April 9 at 6:02 PM
	Vanguard Group Inc. Boosts Stake in Dynavax Technologies Co. (NASDAQ:DVAX) marketbeat.com - April 3 at 4:09 AM
	Dynavax Technologies Co. (NASDAQ:DVAX) Sees Large Increase in Short Interest marketbeat.com - April 2 at 7:18 PM
	Chicago Capital LLC Sells 98,406 Shares of Dynavax Technologies Co. (NASDAQ:DVAX) marketbeat.com - April 2 at 6:36 AM
	Those who invested in Dynavax Technologies (NASDAQ:DVAX) five years ago are up 68% finance.yahoo.com - March 25 at 8:51 AM
	Dynavax Technologies: Still A Believer seekingalpha.com - March 24 at 7:39 AM
	Dynavax Technologies: Still A Believer seekingalpha.com - March 24 at 7:39 AM
	Dynavax: Holding Firm Despite Its Missing Cash Cow seekingalpha.com - March 23 at 8:20 AM
	Dynavax: Holding Firm Despite Its Missing Cash Cow seekingalpha.com - March 23 at 8:20 AM
	Dynavax Technologies Co. (NASDAQ:DVAX) Short Interest Up 9.1% in February marketbeat.com - March 19 at 5:37 PM
	How vaccine maker Dynavax tested itself and found a corporate cure bizjournals.com - March 15 at 1:42 PM
	Dynavax CFO Kelly MacDonald: Making An Impact In The Biotech Industry forbes.com - March 14 at 9:45 AM
	Dynavax Technologies Corporation (DVAX) uk.finance.yahoo.com - March 10 at 12:15 AM
	Chief Accounting Officer Justin Burgess Sells Shares of Dynavax Technologies Corp (DVAX) finance.yahoo.com - March 5 at 12:00 AM
	Dynavax Technologies Corp (DYF1.DU) finance.yahoo.com - February 27 at 11:58 PM
	Dynavax to Present at TD Cowen's 44th Annual Health Care Conference prnewswire.com - February 27 at 6:54 PM
	Overbought China Stock Market Nonetheless Called Higher On Friday finanzen.at - February 24 at 3:40 PM
	Dynavax GAAP EPS of $0.00 beats by $0.01, revenue of $55.6M beats by $2.87M msn.com - February 24 at 3:40 PM
	Dynavax’s Strong Financials and Promising Pipeline Secure Buy Rating markets.businessinsider.com - February 24 at 3:40 PM
	Dynavax’s Strong Financial Outlook and Heplisav-B Market Expansion Prompt ‘Buy’ Rating markets.businessinsider.com - February 23 at 11:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aurinia Pharmaceuticals

NASDAQ:AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Day One Biopharmaceuticals

NASDAQ:DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

DICE Therapeutics

NASDAQ:DICE

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Dynavax Technologies

NASDAQ:DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial